



OPEN

## A meta-analysis on heart rate variability biofeedback and depressive symptoms

Silvia F. M. Pizzoli<sup>1,2✉</sup>, Chiara Marzorati<sup>2</sup>, Daniele Gatti<sup>3</sup>, Dario Monzani<sup>1,2</sup>, Ketti Mazzocco<sup>1,2</sup> & Gabriella Pravettoni<sup>1,2</sup>

Heart rate variability biofeedback (HRVB) has been used for a number of years to treat depressive symptoms, a common mental health issue, which is often comorbid with other psychopathological and medical conditions. The aim of the present meta-analysis is to test whether and to what extent HRVB is effective in reducing depressive symptoms in adult patients. We conducted a literature search on Pubmed, ProQuest, Ovid PsycInfo, and Embase up to October 2020, and identified 721 studies. Fourteen studies were included in the meta-analysis. Three meta-regressions were also performed to further test whether publication year, the questionnaire used to assess depressive symptoms, or the interval of time between T0 and T1 moderated the effect of HRVB. Overall, we analysed 14 RCTs with a total of 794 participants. The random effect analysis yielded a medium mean effect size  $g = 0.38$  [95% CI = 0.16, 0.60; 95% PI = -0.19, 0.96],  $z = 3.44$ ,  $p = 0.0006$ . The total heterogeneity was significant,  $Q_T = 23.49$ ,  $p = 0.03$ ,  $I^2 = 45\%$ , which suggested a moderate variance among the included studies. The year of publication ( $\chi^2(1) = 4.08$ ,  $p = 0.04$ ) and the questionnaire used to assess symptoms ( $\chi^2(4) = 12.65$ ,  $p = 0.01$ ) significantly moderated the effect of the interventions and reduced heterogeneity. Overall, results showed that HRVB improves depressive symptoms in several psychophysiological conditions in adult samples and should be considered as a valid technique to increase psychological well-being.

Depression is one of the most common mental health conditions, globally affecting about 265 million people of all ages (World Health Organization<sup>1</sup>). Low mood, loss of interest, sleep disturbances, reduced appetite, slowed thinking and lack of energy have been identified as potential risk factors for the onset and persistence of other diseases: people suffering from depression are more likely to have substance use issues, personality disorders, or other psychological problems (e.g., distress, anxiety)<sup>2</sup>.

A worldwide study conducted on 245,404 people from 60 different countries, showed that patients suffering from chronic diseases were more likely to show comorbidity with depression<sup>3</sup>. Moreover, depressive symptoms are often associated with poor health outcomes<sup>4</sup>, noncompliance with medications and treatments<sup>5</sup>, and are often comorbid with medical issues such as type 2 diabetes<sup>6</sup> and dementia<sup>7</sup>.

Furthermore, depressive symptoms are associated with a higher risk of cardiovascular disease<sup>8,9</sup>. Patients with heart disease tend to show a higher prevalence of comorbid depression, while post-stroke survivors frequently report depressive symptoms up to 5 years after the cerebrovascular event<sup>10–12</sup>.

Several interventions have been developed to alleviate depressive symptoms: psychotherapy, antidepressant medication, and physical exercises being the most frequent treatments employed<sup>13–15</sup>. Beyond pharmacological treatment, the Health Evidence Network<sup>16</sup> reported that the most effective psychotherapeutic interventions for the depression management are supportive counselling and psychodynamic, interpersonal or cognitive behavioural therapies (CBT). Specifically, different studies have shown that drugs and CBT are equally effective at reducing depressive symptoms in acute, short-term conditions<sup>17</sup>; while CBT has demonstrated greater mid-term and long-term effects than antidepressants<sup>14</sup>. In recent years, new psychotherapeutic approaches have focused on treating depression: mindfulness-based cognitive therapy (MBCT)—a combination of CBT and mindfulness meditation practice—and the so-called “third-wave” therapies have reported significant improvements in depressive symptoms<sup>18–20</sup>. However, these psychotherapeutic approaches do not directly focus on the regulation of physiological outcomes that are highly affected in depressive syndromes<sup>21–23</sup>. Besides psychosocial factors,

<sup>1</sup>Department of Oncology and Hemato-Oncology, University of Milan, Via Festa del Perdono 7, 20122 Milan, Italy. <sup>2</sup>Applied Research Division for Cognitive and Psychological Science, European Institute of Oncology IEO, IRCCS, Milan, Italy. <sup>3</sup>Department of Brain and Behavioral Sciences, University of Pavia, Pavia, Italy. ✉email: silviafrancescamaria.pizzoli@ieo.it

negative emotional symptoms of depression are associated with autonomic nervous system responses, thus involving skin conductance, respiratory and heart rates<sup>21,24,25</sup>.

A key marker of the autonomous nervous system function and a potent predictor of physical morbidity and mortality is heart rate variability (HRV), a measure of the variation in time between each heartbeat. Greater variability indicates greater ability of the autonomic nervous system to regulate itself. This parameter may be used as a diagnostic and predictive bio-marker of depression, since more severe symptoms are significantly associated with reduced HRV<sup>26–28</sup> and reduced HRV itself seems to be implicated in the risk of developing depression<sup>29</sup>.

HRV findings led to the implementation of a new technique widely used in several physical illnesses and mental disorders: HRV Biofeedback (HRVB), a non-invasive therapy training aiming at increasing heart rate oscillations through real time feedback and slow breathing training<sup>30</sup>. This intervention has been implemented for issues in regulating HRV, which were observed in depression treatment<sup>31,32</sup>. Previous studies demonstrated that HRVB improves HRV as measured by standard deviation of normal-to-normal intervals (SDNN), high-frequency power (HF) and low-frequency power/high-frequency power ratio (LF/HF). All of these physiological indices are associated with amelioration of depressive symptoms<sup>26,32,33</sup>.

Numerous studies have demonstrated the positive effect of HRVB in reducing physical and psychological symptoms and increasing wellbeing<sup>34–38</sup>. Furthermore, two meta-analyses were recently conducted to assess the efficacy of biofeedback on mental health.

Goessl et al. conducted a random-effects meta-analysis on the effects of HRVB on symptoms of anxiety and stress, finding that the HRVB is a useful and effective technique for improving self-reported stress and anxiety<sup>39</sup>.

Lehrer et al.<sup>40</sup> recently performed a systematic and meta-analytic review on the efficacy of HRVB and/or paced breathing (approximately six breaths/min) on a wide range of psychological symptoms (including depressive symptoms), mental functions and complex behaviours (such as athletic/artistic performance). The investigators found a significant small effect of HRVB and paced breathing on depression<sup>24</sup>.

However, no meta-analyses have been specifically conducted on randomized controlled studies to investigate the specific effect of HRVB in adults with depressive symptoms (i.e. patients with depressive disorders or with depressive symptoms in comorbidity with other psychological or physical conditions). To fill this gap, the aim of our meta-analysis is to estimate the effect of HRVB in reducing depressive symptoms.

## Material and methods

**Search strategy and inclusion criteria.** To identify potential studies for inclusion in the meta-analysis, we conducted a search of the published literature using the following scientific online databases: Pubmed (all years), Proquest (all years), Ovid PsycInfo (all years), and Embase (all years). Search criteria were: (“heart rate variability biofeedback” OR “HRV biofeedback”) AND (“depression” OR “depressive”). No time restrictions were applied. The full search strategies were reported in Online Appendix A.

The literature search was conducted up to October 2020.

**Study selection.** One of the authors conducted a systematic literature search. Two other authors selected papers for full review based on inclusion and exclusion criteria and assessed their eligibility. Agreement was reached on the final selection of included studies.

Inclusion criteria were: (1) English-language publication, (2) work included an HRV biofeedback intervention, (3) randomized clinical trial (RCT), (4) peer-reviewed publication, and (5) work involved adult participants.


**Review strategy and data extraction.** A total of 721 articles were identified and retrieved. After the first screening of title and abstract, 134 studies remained. After a full-text examination, 95 studies were excluded. 2 studies reported incomplete data<sup>41,42</sup>; corresponding authors were contacted, none provided the requested data, and those studies were therefore excluded. The remaining 14 studies were included in the present meta-analysis<sup>26,35,43–54</sup>.

Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines were applied. The flowchart is shown in Fig. 1.

**Effect size calculation.** The level of depressive symptoms was our dependent variable of interest. From each study we extracted: sample size, and mean and standard deviation of participants’ scores in the various conditions for the variable of interest.

The effect size used was *Hedges’ g*<sup>55</sup>, which is a standardized mean difference that accounts for sampling variance difference between conditions. The effect size and variance calculation were performed using R-Studio (RStudio Team 2015) and its package *compute.es*<sup>56</sup> using the command *mes* when mean and standard deviations were available or *pes* when only *p*-values were reported. Effect sizes were computed comparing participants measures at time 1 (T1) between intervention vs. control group. This criterion was violated only for one study<sup>45</sup>, in which T1 was at 2 weeks and time 2 (T2) at 5 weeks; in this case we used T2 values. We decided to use the data collected at T2 in order to improve timing coordination with the other included studies, which all had T1s at least at 4 weeks after the end of the training.

**Risk of bias assessment.** Risk of bias was assessed with the tool recommended by Cochrane guidelines<sup>57</sup>. Included RCTs were analysed according to random sequence generation, allocation concealment, blinding of participants and personnel, blinding of outcome assessment, incomplete outcome data, selective reporting, and other bias. Each source of bias was rated as yes (“low risk of bias”), no (“high risk of bias”), or unclear (“moderate risk of bias”). Disagreements in bias scoring were resolved by discussions among the two reviewers.



**Figure 1.** Flowchart illustrating study selection, review strategy and data extraction.

**Data analysis.** In order to assess whether HRVB can successfully reduce depressive symptoms and quantify the effect of the modulation, we performed one random-effects meta-analysis using the restricted maximum-likelihood estimation method. We also carried out three distinct meta-regressions to assess whether the year of publication of the study, the test used to evaluate depressive symptoms, or the timing of T1, moderated the observed effect.

The within-studies heterogeneity was evaluated using the  $Q$ -test. A significant  $p$ -value of the  $Q$ -test implies that the observed within-studies variance can be explained by other variables besides HRVB. In addition, we used as index of heterogeneity Higgins'  $I^2$ <sup>58</sup>, which provides the percentage of the total variability in the effect size estimation that could be attributed to heterogeneity among the true effects (heterogeneity is considered high if  $I^2 > 75\%$ , Higgins et al.<sup>58</sup>). To further investigate heterogeneity, we also computed prediction intervals ( $PI$ ) of the effect, which quantify the dispersion of effect. That is, 95%  $PI$  indicate the range of values that the effect size of a future study similar to those included should probably take (Borenstein et al.<sup>55</sup>).

Publication bias was evaluated using funnel plots and the trim-and-fill method (Duval 2005). The trim-and-fill method provides an estimate the number of studies missing from the meta-analysis due to the suppression of the most extreme results on one side (generally the left, i.e., non-significant results) of the plot. To further explore the publication bias, the Egger's test<sup>59</sup> was performed. The Egger's test examines the correlation between the various effect sizes and their sampling variances (i.e., if the funnel plot is asymmetric), and a significant  $p$ -value indicates publication bias<sup>60</sup>. To explore the robustness of the results, we performed a leave-one-out analysis: this procedure evaluates the robustness of the effect excluding one study at a time. The meta-analyses performed, and the related plots were computed using the R-package metafor<sup>61</sup>.

## Results

**Summary of findings.** The characteristics of the included trials are reported in Online Appendix B. The studies included in our meta-analysis were conducted between 2009 and 2020. The sample size varied from 20 to 134; all the studies used a between-subject design. A total of 14 RCTs were analysed on a total of 794 patients divided into experimental ( $M$  age = 46.17  $SD$  = 7.72, 42.72% female) and control ( $M$  age = 46.81,  $SD$  = 7.17, 44.5% female) groups. Among the studies, two were conducted in Taiwan<sup>35,43</sup>, two in Netherlands<sup>44,47</sup>, three in the USA<sup>26,46,54</sup>, three in Germany<sup>45,49</sup>, one in the UK, one in Austria, one in Iran and one in Sweden<sup>48,50,51,53</sup>. Nine studies were conducted on patients with cardiovascular disease, stress symptoms, cancer or alcohol disorder, while the remaining five studies focused on non-clinical samples<sup>26,44,47,48,52</sup>.

Of the 14 studies included, all evaluated depression with reliable instruments: six assessed depression through the BDI-II<sup>62</sup>, four through the DASS<sup>63</sup>, two through the HADS<sup>43</sup>, one employed the PHQ-9<sup>64</sup> and one the CED-S<sup>65</sup>. Overall, the time range of the follow up ranged from five weeks post end-of-intervention<sup>48,53</sup>, to 12 months after the intervention<sup>35,53</sup>.

**Risk of bias.** Figure 2 reported risk of bias assessment. None of the included studies withheld information on interventions from trial participants. Eight trials did not report how randomization was performed. In seven studies, the assessment of outcomes by researchers was blinded. Overall, most information was from trials at low or unclear risk of bias.

**HRVB and depressive symptoms.** The random effect analysis ( $N=14$ ) showed a medium mean effect size,  $g=0.38$  [95%  $CI$  0.16, 0.60; 95%  $PI$  = -0.19, 0.96],  $z=3.44$ ,  $p=0.0006$ , meaning that HRVB has a positive effect in reducing depressive symptoms. Total heterogeneity was significant,  $Q_T=23.49$ ,  $p=0.03$ ,  $I^2=45\%$ , suggesting moderate variance across the studies included (Fig. 3).

The sensitivity analysis showed that the effect size ranged between 0.33 and 0.42 ( $M=0.38$ ,  $SD=0.03$ ). The trim-and-fill method added no hypothetical missing studies on the left side of the funnel plot (Fig. 4). The Eggers test was not significant,  $z=0.85$ ,  $p=0.39$ , suggesting no publication bias.

The meta-regression performed using the year of publication as moderator ( $N=14$ ) showed that the test on the moderator was significant,  $\chi^2(1)=4.08$ ,  $p=0.04$ ,  $estimate=0.06$ . The heterogeneity became not significant,  $Q_T=18.14$ ,  $p=0.11$ , and Higgins'  $I^2$  decreased,  $I^2=0\%$ . The decrease in heterogeneity suggests that the year of publication plays a role in determining the differences in the effects reported by the various studies; in particular, most recent studies reported higher effect sizes (Fig. 5).

The meta-regression performed using the test used to evaluate depressive symptoms as moderator ( $N=14$ ) showed that the test on the moderator was significant,  $\chi^2(4)=12.65$ ,  $p=0.01$ . The heterogeneity became not significant,  $Q_T=10.23$ ,  $p=0.33$ , and Higgins'  $I^2$  decreased,  $I^2=7\%$ . The decrease in heterogeneity suggests that the test used to evaluate depressive symptoms plays a role in determining the differences in the effects reported by the various studies. Critically, when depressive symptoms were assessed using CES-D, the effect size was not significantly different from zero, while when they were measured by means of BDI-II, DASS, HADS or PHQ-9 the effect size was significantly different from zero (Table 1).

The meta-regression performed using the timing of T1 as moderator ( $N=14$ ) showed that the test on the moderator was not significant,  $\chi^2(1)=1.40$ ,  $p=0.23$ ,  $estimate=0.09$ . The heterogeneity remained significant,  $Q_T=21.30$ ,  $p=0.04$ , and Higgins'  $I^2$  remained stable,  $I^2=43\%$ . The lack of effect of the moderator suggests that timing of T1 does not play a role in determining the differences in the effects reported by the various studies.

## Discussion

To the best of our knowledge, this is the first meta-analysis of RCTs on the impact of HRVB on the reduction of depressive symptoms in different pathological conditions in adult samples.

We selected and analysed 14 published RCTs, including a total of 794 subjects, and examined the effectiveness of HRVB for symptoms of depression in adults compared to control conditions or other active treatments.

Overall, we observed that the HRVB exert a positive and statistically significant (moderate) effect in reducing depressive symptoms after intervention, compared to other control and active conditions. This is partially in line with the significant effect found in the recent meta-analysis on HRVB and/or paced breathing by Lehrer et al.<sup>40</sup>. Considering the previous recent meta-analysis, which found a significant yet small effect size of HRV on depression, we found a slightly higher effect. Such a difference might be due to the fact that Lehrer et al.<sup>40</sup> assessed the efficacy of both HRVB and paced-breathing and that we included five recent studies<sup>43,51–54</sup>, which were not included in the previous meta-analysis.


We found statistically significant heterogeneity, indicating moderate variance across the included studies. However, when testing for the role of two (i.e., the year of publication of the study and the test used to evaluate depressive symptoms) of the three moderators included in the meta-regressions, heterogeneity decreased and became not significant. Conversely, the timing of T1 did not moderate the observed effect, a result which is in line with the previous meta-analysis<sup>40</sup>, which found that the length of interventions did not influence the effect size.

The effects of the moderators “year of publication” and “questionnaire used” were significant, suggesting that both predictors played a role in determining the effect of HRVB on depressive symptoms.


The year of publication moderated the effect of the intervention, in the direction of larger effect sizes for recent studies. The most recent studies we included had usual care and active control groups and conducted the interventions on participants with heterogeneous features (cardiovascular disease, psychiatric illnesses and no medical condition)<sup>43,51–54</sup>, thus it is unlikely that those specific features had an influence in moderating the effects.

	Random sequence generation (selection bias)	Allocation concealment (selection bias)	Blinding of participants and personnel (performance bias)	Blinding of outcome assessment (detection bias)	Incomplete outcome data (attrition bias)	Selection reporting (reporting bias)	Other bias
Amjadian et al., 2020	?	?	×	×	✓	✓	✓
Brinkmann et al., 2020	✓	✓	×	✓	✓	✓	✓
Burch et al., 2020	✓	✓	×	✓	✓	✓	✓
Chang et al., 2020	✓	✓	×	✓	✓	✓	✓
Tatschl et al., 2020	?	✓	×	×	✓	✓	✓
Van der Zwan et al., 2019	?	✓	×	×	✓	✓	✓
Caldwell et al., 2018	?	×	×	×	✓	✓	✓
Yu et al., 2018	?	✓	×	✓	✓	✓	✓
Windthorst et al., 2017	?	✓	×	×	✓	✓	✓
Penzlin et al., 2015	✓	✓	×	✓	✓	✓	✓
Van der Zwan et al., 2015	✓	✓	×	×	✓	✓	✓
Gruzelier et al., 2014	?	✓	×	×	✓	✓	✓
Hallman et al., 2011	?	×	×	✓	✓	✓	✓
Swanson et al., 2009	✓	✓	×	✓	?	✓	✓

**Figure 2.** Risk of bias assessment. Low risk of bias is represented with green dots, high risk of bias in red, unclear risk of bias in yellow.




**Figure 3.** Forest plot, each square corresponds to one study and the lines represent 95% confidence interval. The size of each square represents the weight of the study. The diamond at the bottom represents the cumulative effect size with 95% confidence interval. Higher positive values indicate greater effect of the HRVB intervention compared with the control group.



**Figure 4.** Funnel plot. Black dots represent studies included in the present meta-analysis. The vertical line represents the effect size.

It is possible that in recent years biofeedback devices may have become easier and more user-friendly for participants, capable of giving more sophisticated visual feedback, and thus contributing to increased effectiveness of HRVB.

Considering the effect of the test employed, we found that the significant positive *Hedges' g* ranged from small to high effect sizes (0.23–1.10) and that the only questionnaire which was associated with a non-significant effect



**Figure 5.** Plot illustrating the relationship between year of publication and cumulative effect sizes. In particular, the most recent the study, the greater the effect size. The area of the points is proportional to study variances. Three studies published in 2020 are not reported due to overlapping positions. Dashed lines indicate 95% CI, the dotted line indicate Hedges'  $g = 0$  (i.e., no difference between groups).

TEST	BDI-II	CES-D	DASS	HADS	PHQ-9
Hedges' $g$	0.23	- 0.41	0.48	0.85	1.10
95% CI	[0.01, 0.45]	[- 1.13, 0.31]	[0.17, 0.80]	[0.33, 1.36]	[0.25, 1.94]
Number of studies	$N=6$	$N=1$	$N=4$	$N=2$	$N=1$

**Table 1.** Hedges'  $g$  calculated using the questionnaire used to evaluate depressive symptoms as moderator.

was CES-D. These findings should be interpreted with caution, since only one study employed CES-D as an instrument<sup>46</sup> and it was the unique study that did not find an improvement of depressive symptoms. Thus, the numerosity of the studies using a specific questionnaire might have influenced the significance of the moderation. However, considering these results, we believe that future studies should be conducted in which the specific features of depression of interest to researchers and clinicians are carefully chosen, with particular consideration given to the time range of the interventions.

In the present meta-analysis, the questionnaires were designed to assess the presence, the severity or the frequency of depressive symptoms only (BDI-II, CES-D, PHQ-9) or of depressive signs together with other symptoms (HADS, DASS) in a time period ranging from 1 week prior to the administration (CES-D, HADS, DASS) to 2 weeks before (PHQ-9, BDI-II) among heterogeneous samples. These might be among the reasons why questionnaires were found to moderate the efficacy of the interventions. We speculate that for HRVB studies, questionnaires that screen for the presence of symptoms within 1 week before the time of administration might provide a more precise picture of the efficacy of the interventions, since those that measure the presence of symptoms for 2 weeks before have a fair degree of overlap with the period of the intervention itself.

We consider the results of the present meta-analysis to be reliable, due to our test and adjustment for publication bias. Specifically, we utilized the rank-based trim-and-fill method, which assesses and adjusts results for publication bias depending on funnel plot asymmetry. According to the trim-and-fill method and to the Egger's test, our results were minimally impacted by publication bias.

Furthermore, the robustness of results, evaluated through a sensitivity analysis, yielded results consistent with the conclusion that HRVB interventions have a positive effect on depressive symptoms. That is, the exclusion of one study at a time through the sensitivity analysis showed the results are not driven by the effect size of only one study. Indeed, the effect size ranged between .33 and 0.42 with a low standard deviation ( $SD=0.03$ ).

Additionally, consistent with our findings, two studies excluded in the selection procedure due to lack of data<sup>41,42</sup> reported a decrease in depressive symptoms in biofeedback groups compared to the control group.

**Clinical implications.** Depression is one of the most widespread mental diseases, and it occurs in people of all ages across all world regions with more than 264 million people affected (World Health Organization<sup>1</sup>).

Furthermore, people with multimorbidity are two to three times more likely to have depression compared to people without multimorbidity or those who have no chronic physical condition<sup>66</sup>.

Autonomic changes are often found in altered mood states and appear to be a central biological substrate linking depression to several physical dysfunctions<sup>23</sup>.

Among autonomic indexes, heart rate variability (HRV) is a significant health marker. Critically, the decrease in HRV that occurs during depression states does not return to normal levels as a consequence of existing psychotherapy or pharmacological treatment, even when the psychological outcome is positive<sup>26</sup>. It is worth noting that HRV may also inform research into the prevention and treatment of depression in later life<sup>24</sup>.

Our findings suggest that HRVB is an effective intervention for the reduction of depressive symptomatology when compared to control or active conditions and, even more importantly, HRVB yielded an effect size that is comparable to other broadly applied approaches (such as CBT)<sup>67</sup>. Interestingly, HRVB intervention is effective also in the treatment of anxiety and perceived stress, with a high reduction of symptoms (*Hedges' g* = 0.83) in treated groups compared to controls<sup>39</sup>. As a consequence, HRVB might constitute a valuable intervention for patients with symptoms of both anxiety and depression, which often co-occur in the same individual and that can be considered bi-directional risk factor for one another<sup>68</sup>.

Furthermore, the possibility of treating depressive symptoms (and anxiety) among patients with other physical diseases, might render HRVB a suitable intervention for patients with both distressing physical conditions and an emotional burden, such as cancer patients<sup>69,70</sup>.

**Limitations and future directions.** To date, there is no specific evidence on which specific pathophysiological conditions, among those included in the present meta-analysis, might derive most benefit from HRVB intervention; nor can it be concluded which biofeedback protocol and devices yield the best results.

As things currently stand, conclusions on specific subsamples or on the severity of the symptoms cannot be drawn. More RCTs are warranted to clarify the effect on specific samples and to perform subgroup analyses according to clinical characteristics of the sample. Such analyses would lead to the possibility of personalizing the interventions based upon the particular characteristics of each individual patient<sup>71,72</sup>.

Furthermore, the measurements of depression in patients presently rely on a subjective scale, and even though we included studies which made use of reliable and standardized scales, the lack of objective assessment might have introduced a risk of bias in the measurement of the relevant outcomes. Thus, measurement tools that provide data with higher reliability and validity should be utilized in future studies, possibly employing objective measurements, such as neuroimaging data<sup>73</sup>. Furthermore, questionnaires might be used to assess which specific depressive features are alleviated by biofeedback (for example, somatic complaints and cognitive signs).

## Conclusions

According to the present meta-analysis, HRVB offers a useful tool for treating depressive symptoms in patients with psychological or medical diseases, although its effectiveness on specific conditions remains unclear. Further studies are warranted to assess which specific HRVB protocols lead to greater results for treating depressive symptoms among adults.

Received: 5 November 2020; Accepted: 8 March 2021

Published online: 23 March 2021

## References

- World Health Organization. *Depression and Other Common Mental Disorders Global Health Estimates* (WHO, 2017).
- Hasin, D. S. *et al.* Epidemiology of adult DSM-5 major depressive disorder and its specifiers in the United States. *JAMA Psychiatry* **75**(4), 336–346. <https://doi.org/10.1001/jamapsychiatry.2017.4602> (2018).
- Moussavi, S. *et al.* Depression, chronic diseases, and decrements in health: Results from the World Health Surveys. *Lancet* **370**(9590), 851–858. [https://doi.org/10.1016/S0140-6736\(07\)61415-9](https://doi.org/10.1016/S0140-6736(07)61415-9) (2007).
- Penninx, B. W. J. H., Milaneschi, Y., Lamers, F. & Vogelzangs, N. Understanding the somatic consequences of depression: Biological mechanisms and the role of depression symptom profile. *BMC Med.* <https://doi.org/10.1186/1741-7015-11-129> (2013).
- DiMatteo, M. R., Lepper, H. S. & Croghan, T. W. Depression is a risk factor for noncompliance with medical treatment meta-analysis of the effects of anxiety and depression on patient adherence. *Arch. Intern. Med.* **160**(14), 2101–2107 (2000).
- Knol, M. J. *et al.* Depression as a risk factor for the onset of type 2 diabetes mellitus. A meta-analysis. *Diabetologia* **49**(5), 837–845 (2006).
- Green, R. C. *et al.* Depression as a risk factor for Alzheimer disease: The MIRAGE study. *Arch. Neurol.* **60**(5), 753–759 (2003).
- Correll, C. U. *et al.* Prevalence, incidence and mortality from cardiovascular disease in patients with pooled and specific severe mental illness: A large-scale meta-analysis of 3,211,768 patients and 113,383,368 controls. *World Psychiatry* **16**(2), 163–180 (2017).
- Lett, H. S. *et al.* Depression as a risk factor for coronary artery disease: Evidence, mechanisms, and treatment. *Psychosom. Med.* **66**, 305–315 (2004).
- Kang, H.-J. *et al.* Comorbidity of depression with physical disorders: Research and clinical implications. *Chonnam Med. J.* **51**(1), 8–18. <https://doi.org/10.4068/cmj.2015.51.1.8> (2015).
- Roth, D. L. *et al.* Depressive symptoms after ischemic stroke: Population-based comparisons of patients and caregivers with matched controls. *Stroke* **51**(1), 54–60. <https://doi.org/10.1161/STROKEAHA.119.027039> (2020).
- Davidson, K. W., Alcántara, C. & Miller, G. E. Selected psychological comorbidities in coronary heart disease: Challenges and grand opportunities. *Am. Psychol.* **73**(8), 1019–1030. <https://doi.org/10.1037/amp0000239> (2018).
- Kvam, S., Kleppe, C. L., Nordhus, I. H. & Hovland, A. Exercise as a treatment for depression: A meta-analysis. *J. Affect. Disord.* **202**, 67–86 (2016).
- Li, J. M. *et al.* Cognitive behavioral therapy for treatment-resistant depression: A systematic review and meta-analysis. *Psychiatry Res.* **268**, 243–250. <https://doi.org/10.1016/j.psychres.2018.07.020> (2018).
- Gordon, B. R. *et al.* Association of efficacy of resistance exercise training with depressive symptoms meta-analysis and meta-regression: Analysis of randomized clinical trials. *JAMA Psychiatry* **75**(6), 566–576 (2018).



16. Möller, H. & Henkel, V. *What are the Most Effective Diagnostic and Therapeutic Strategies for the Management of Depression in Specialist Care?* (WHO Regional Office for Europe, 2005).
17. DeRubeis, R. J., Siegle, G. J. & Hollon, S. D. Cognitive therapy versus medication for depression: Treatment outcomes and neural mechanisms. *Nat. Rev. Neurosci.* **9**(10), 788–796 (2008).
18. Hagen, R. *et al.* Metacognitive therapy for depression in adults: A waiting list randomized controlled trial with six months follow-up. *Front. Psychol.* **8**, 31. <https://doi.org/10.3389/fpsyg.2017.00031> (2017).
19. Donker, T. *et al.* Predictors and moderators of response to internet-delivered interpersonal psychotherapy and cognitive behavior therapy for depression. *J. Affect. Disord.* **151**(1), 343–351. <https://doi.org/10.1016/j.jad.2013.06.020> (2013).
20. Seligman, L. & Reichenberg, L. *Theories of Counseling and Psychotherapy: Systems, Strategies, and Skills* 354–356 (Pearson Higher Education, 2014).
21. Lin, H. P., Lin, H. Y., Lin, W. L. & Huang, A. C. W. Effects of stress, depression, and their interaction on heart rate, skin conductance, finger temperature, and respiratory rate: Sympathetic-parasympathetic hypothesis of stress and depression. *J. Clin. Psychol.* **67**(10), 1080–1091. <https://doi.org/10.1002/jclp.20833> (2011).
22. Kemp, A. H., Quintana, D. S., Felmingham, K. L., Matthews, S. & Jelinek, H. F. Depression, comorbid anxiety disorders, and heart rate variability in physically healthy, unmedicated patients: Implications for cardiovascular risk. *PLoS ONE* **7**(2), e30777 (2012).
23. Sgoifo, A., Carnevali, L., Pico Alfonso, M. D. L. A. & Amore, M. Autonomic dysfunction and heart rate variability in depression. *Stress* **18**(3), 343–352. <https://doi.org/10.3109/10253890.2015.1045868> (2015).
24. Brown, L. *et al.* Heart rate variability alterations in late life depression: A meta-analysis. *J. Affect. Disord.* **235**, 456–466. <https://doi.org/10.1016/j.jad.2018.04.071> (2018).
25. Kidwell, M. & Ellenbroek, B. A. Heart and soul: Heart rate variability and major depression. *Behav. Pharmacol.* **29**(2), 152–164. <https://doi.org/10.1097/FBP.0000000000000387> (2018).
26. Caldwell, Y. T. & Steffen, P. R. Adding HRV biofeedback to psychotherapy increases heart rate variability and improves the treatment of major depressive disorder. *Int. J. Psychophysiol.* **2018**(131), 96–101. <https://doi.org/10.1016/j.ijpsycho.2018.01.001> (2017).
27. Hartmann, R., Schmidt, F. M., Sander, C. & Hegerl, U. Heart rate variability as indicator of clinical state in depression. *Front. Psychiatry* **9**, 735. <https://doi.org/10.3389/fpsyg.2018.00735> (2019).
28. Kemp, A. H. *et al.* Impact of depression and antidepressant treatment on heart rate variability: A review and meta-analysis. *Biol. Psychiatry* **67**(11), 1067–1074. <https://doi.org/10.1016/j.biopsych.2009.12.012> (2010).
29. Dell'Acqua, C., Dal Bò, E., Messerotti Benvenuti, S. & Palomba, D. Reduced heart rate variability is associated with vulnerability to depression. *J. Affect. Disord. Rep.* **1**, 100006. <https://doi.org/10.1016/j.jadr.2020.100006> (2020).
30. Lehrer, P. M., Vaschillo, E. & Vaschillo, B. Resonant frequency biofeedback training to increase cardiac variability: Rationale and manual for training. *Appl. Psychophysiol. Biofeedback* **25**, 177–191 (2000).
31. Lehrer, P. M. & Gevirtz, R. Heart rate variability biofeedback: How and why does it work? *Front. Psychol.* **5**, 756. <https://doi.org/10.3389/fpsyg.2014.00756> (2014).
32. Lin, I. M. *et al.* Heart rate variability biofeedback increased autonomic activation and improved symptoms of depression and insomnia among patients with major depression disorder. *Clin. Psychopharmacol. Neurosci.* **17**(2), 222. <https://doi.org/10.9758/cpn.2019.17.2.222> (2019).
33. Karavidas, M. *Heart Rate Variability Biofeedback for Major Depression* (Biofeedback, 2008).
34. Jimenez Morgan, S. & Molina Mora, J. A. Effect of heart rate variability biofeedback on sport performance, a systematic review. *Appl. Psychophysiol.* **42**(3), 235–245 (2017).
35. Yu, L. C., Lin, I. M., Fan, S. Y., Chien, C. L. & Lin, T. H. One-year cardiovascular prognosis of the randomized, controlled, short-term heart rate variability biofeedback among patients with coronary artery disease. *Int. J. Behav. Med.* **25**(3), 271–282. <https://doi.org/10.1007/s12529-017-9707-7> (2018).
36. Criswell, S. R., Sherman, R. & Krippner, S. Cognitive behavioral therapy with heart rate variability biofeedback for adults with persistent noncombat-related posttraumatic stress disorder. *Perm. J.* <https://doi.org/10.7812/TPP/17-207> (2018).
37. Drury, R. L., Porges, S. W., Thayer, J. F. & Ginsberg, J. Editorial: Heart rate variability, health and well-being: A systems perspective. *Front. Public Health* **7**, 323 (2019).
38. Yetwin, A., Marks, K., Bell, T. & Gold, J. Heart rate variability biofeedback therapy for children and adolescents with chronic pain. *J. Pain* **13**(4), S93. <https://doi.org/10.1016/j.jpain.2012.01.386> (2012).
39. Goessl, V. C., Curtiss, J. E. & Hofmann, S. G. The effect of heart rate variability biofeedback training on stress and anxiety: A meta-analysis. *Psychol. Med.* **47**(15), 2578–2586 (2017).
40. Lehrer, P. *et al.* Heart rate variability biofeedback improves emotional and physical health and performance: A systematic review and meta analysis. *Appl. Psychophysiol.* **45**, 109–129 (2020).
41. Klimov, D. *et al.* Biofeedback on heart rate variability in cardiac rehabilitation: Practical feasibility and psycho-physiological effects. *Acta Cardiol.* **69**(3), 299–307. <https://doi.org/10.1080/ac.69.3.3027833> (2014).
42. Meyer, P. W., Friederich, H. C. & Zastrow, A. Breathe to ease—Respiratory biofeedback to improve heart rate variability and coping with stress in obese patients: A pilot study. *Ment. Health Prev.* **11**, 41–46. <https://doi.org/10.1016/j.mhp.2018.06.001> (2018).
43. Chang, W. L. *et al.* Effects of heart rate variability biofeedback in patients with acute ischemic stroke: A randomized controlled trial. *Biol. Res. Nurs.* **22**(1), 34–44. <https://doi.org/10.1177/1099800419881210> (2020).
44. Van der Zwan, J. E., Huizink, A. C., Lehrer, P. M., Koot, H. M. & de Vente, W. The effect of heart rate variability biofeedback training on mental health of pregnant and non-pregnant women: A randomized controlled trial. *Int. J. Environ. Res. Public Health.* <https://doi.org/10.3390/ijerph16061051> (2019).
45. Penzlin, A. I., Siepmann, T., Illigens, B. M. W., Weidner, K. & Siepmann, M. Heart rate variability biofeedback in patients with alcohol dependence: A randomized controlled study. *Neuropsychiatr. Dis. Treat.* **11**, 2619–2627. <https://doi.org/10.2147/NDT.S84798> (2015).
46. Swanson, K. S. *et al.* The effect of biofeedback on function in patients with heart failure. *Appl. Psychophysiol.* **34**(2), 71–91. <https://doi.org/10.1007/s10484-009-9077-2> (2009).
47. Van der Zwan, J. E., de Vente, W., Huizink, A. C., Bogels, S. M. & de Bruin, E. I. Physical activity, mindfulness meditation, or heart rate variability biofeedback for stress reduction: A randomized controlled trial. *Appl. Psychophysiol.* **40**(4), 257–268 (2015).
48. Gruzelier, J. H., Thompson, T., Redding, E., Brandt, R. & Steffert, T. Application of alpha/theta neurofeedback and heart rate variability training to young contemporary dancers: State anxiety and creativity. *Int. J. Psychophysiol.* **93**(1), 105–111 (2014).
49. Windthorst, P. *et al.* Heart rate variability biofeedback therapy and graded exercise training in management of chronic fatigue syndrome: An exploratory pilot study. *J. Psychosom. Res.* **93**, 6–13 (2017).
50. Hallman, D. M., Olsson, E. M. G., Von Scheele, B., Melin, L. & Lyskov, E. Effects of heart rate variability biofeedback in subjects with stress-related chronic neck pain: A pilot study. *Appl. Psychophysiol.* **36**(2), 71–80. <https://doi.org/10.1007/s10484-011-9147-0> (2011).
51. Amjadian, M. *et al.* A pilot randomized controlled trial to assess the effect of Islamic spiritual intervention and of breathing technique with heart rate variability feedback on anxiety, depression and psycho-physiologic coherence in patients after coronary artery bypass surgery. *Ann. Gen. Psychiatry* **19**(1), 1–10. <https://doi.org/10.1186/s12991-020-00296-1> (2020).
52. Brinkmann, A. E. *et al.* Comparing effectiveness of HRV-biofeedback and mindfulness for workplace stress reduction: A randomized controlled trial. *Appl. Psychophysiol.* **45**, 307. <https://doi.org/10.1007/s10484-020-09477-w> (2020).

53. Tatschl, J. M., Hochfellner, S. M. & Schwerdtfeger, A. R. Implementing mobile HRV biofeedback as adjunctive therapy during inpatient psychiatric rehabilitation facilitates recovery of depressive symptoms and enhances autonomic functioning short-term: A 1-year pre–post-intervention follow-up pilot study. *Front. Neurosci.* **14**, 1–14. <https://doi.org/10.3389/fnins.2020.00738> (2020).
54. Burch, J. B. *et al.* Symptom management among cancer survivors: Randomized pilot intervention trial of heart rate variability biofeedback. *Appl. Psychophysiol.* **45**(2), 99–108 (2020).
55. Borenstein, M., Hedges, L. V., Higgins, J. P. T. & Rothstein, H. R. *Introduction to Meta-Analysis* (Wiley, 2009).
56. Del Re, A. C. *compute.es: Compute Effect Sizes. R package version 0.2–2.* <http://cran.r-project.org/web/packages/compute.es>. Accessed 5 Sept 2020 (2013).
57. Higgins, J. P. T. *et al.* The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. *BMJ* **343**, d5928 (2011).
58. Higgins, J. P. T., Thompson, S. G., Deeks, J. J. & Altman, D. G. Measuring inconsistency in meta-analyses. *Br. Med. J.* **327**(7414), 557–560 (2003).
59. Egger, M., Smith, G. D., Schneider, M. & Minder, C. Bias in meta-analysis detected by a simple, graphical test. *Br. Med. J.* **315**(7109), 629–634 (1997).
60. Lin, L. & Chu, H. Quantifying publication bias in meta-analysis. *Biometrics* **74**(3), 785–794 (2018).
61. Viechtbauer, W. Conducting meta-analyses in R with the metafor. *J. Stat. Softw.* **36**(3), 1–48 (2010).
62. Beck, A. T., Steer, R. A. & Brown, G. K. *Manual for the Beck Depression Inventory-II* (TX Psychol Corp, 1996).
63. Lovibond, S. H. & Lovibond, P. F. *Manual for the Depression Anxiety Stress Scales* (Psychology Foundation of Australia, 1995).
64. Spitzer, R. L., Kroenke, K. & Williams, J. B. W. Validation and utility of a self-report version of PRIME-MD: The PHQ primary care study. *J. Am. Med. Assoc.* **282**(18), 1737–1744. <https://doi.org/10.1001/jama.282.18.1737> (1999).
65. Radloff, L. S. The CES-D scale: A self-report depression scale for research in the general population. *Appl. Psychol. Meas.* **1**, 385–401. <https://doi.org/10.1177/014662167700100306> (1977).
66. Read, J. R., Sharpe, L., Modini, M. & Dear, B. F. Multimorbidity and depression: A systematic review and meta-analysis. *J. Affect. Disord.* **15**(221), 36–46. <https://doi.org/10.1016/j.jad.2017.06.009> (2017).
67. Cuijpers, P. *et al.* A meta-analysis of cognitive-behavioural therapy for adult depression, alone and in comparison with other treatments. *Can. J. Psychiatry* **58**(7), 376–385 (2013).
68. Jacobson, N. C. & Newman, M. G. Anxiety and depression as bidirectional risk factors for one another: A meta-analysis of longitudinal studies. *Psychol. Bull.* **143**(11), 1155–1200. <https://doi.org/10.1037/bul0000111> (2017).
69. Mitchell, A. J. *et al.* Prevalence of depression, anxiety, and adjustment disorder in oncological, haematological, and palliative-care settings: A meta-analysis of 94 interview-based studies. *Lancet Oncol.* **12**(2), 160–174 (2011).
70. Mazzocco, K., Masiero, M., Carriero, M. C. & Pravettoni, G. The role of emotions in cancer patients' decision-making. *Ecancermedicalscience*. <https://doi.org/10.3332/ecancer.2019.914> (2019).
71. Pravettoni, G. & Gorini, A. A P5 cancer medicine approach: Why personalized medicine cannot ignore psychology. *J. Eval. Clin. Pract.* **17**(4), 594–596 (2011).
72. Kondylakis, H. *et al.* Development of interactive empowerment services in support of personalised medicine. *Ecancermedicalscience*. <https://doi.org/10.3332/ecancer.2014.400> (2014).
73. Salvadore, G. *et al.* Prefrontal cortical abnormalities in currently depressed versus currently remitted patients with major depressive disorder. *Neuroimage* **54**(4), 2643–2651 (2011).

## Acknowledgements

Authors thank William Russell-Edu for the editing of the English language.

## Author contributions

S.F.M.P. and C.M. conceived the initial idea for the study, performed the systematic literature search and systematized the data; S.F.M.P. and D.G. analysed and discussed the data, while D.M. supervised the systematic literature search, the analyses and contributed to the methodology. All the aforementioned authors wrote the initial draft of the manuscript. K.M. revised the initial draft, discussed the clinical implications of the study, and supervised the entire process. G.P. supervised and revised all the steps of the manuscript and the drafts. All the authors discussed every step of the manuscript.

## Competing interests

The authors declare no competing interests.

## Additional information

**Supplementary Information** The online version contains supplementary material available at <https://doi.org/10.1038/s41598-021-86149-7>.

**Correspondence** and requests for materials should be addressed to S.F.M.P.

**Reprints and permissions information** is available at [www.nature.com/reprints](http://www.nature.com/reprints).

**Publisher's note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.



**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2021